We demonstrate here for the first time that SGLT2i therapy increased islet insulin content, and decreased proinsulin levels through reduction in β-cell oxidative and ER stress in mouse models of monogenic NDM and obese/T2D. This evidence concerns the gene INS and neonatal diabetes mellitus.